EXELIXIS INC (1EXEL.MI) Stock Fundamental Analysis

BIT:1EXEL • US30161Q1040

30.7 EUR
-2.85 (-8.49%)
Last: Oct 22, 2025, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

8

1EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. 1EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. 1EXEL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes 1EXEL very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • 1EXEL had positive earnings in the past year.
  • 1EXEL had a positive operating cash flow in the past year.
  • Each year in the past 5 years 1EXEL has been profitable.
  • In the past 5 years 1EXEL always reported a positive cash flow from operatings.
1EXEL.MI Yearly Net Income VS EBIT VS OCF VS FCF1EXEL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • 1EXEL has a Return On Assets of 22.49%. This is amongst the best in the industry. 1EXEL outperforms 91.89% of its industry peers.
  • With an excellent Return On Equity value of 29.62%, 1EXEL belongs to the best of the industry, outperforming 90.54% of the companies in the same industry.
  • 1EXEL has a Return On Invested Capital of 25.22%. This is amongst the best in the industry. 1EXEL outperforms 97.30% of its industry peers.
  • 1EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is in line with the industry average of 12.19%.
  • The 3 year average ROIC (10.78%) for 1EXEL is below the current ROIC(25.22%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROIC 25.22%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1EXEL.MI Yearly ROA, ROE, ROIC1EXEL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

  • Looking at the Profit Margin, with a value of 27.01%, 1EXEL belongs to the top of the industry, outperforming 86.49% of the companies in the same industry.
  • 1EXEL's Profit Margin has declined in the last couple of years.
  • The Operating Margin of 1EXEL (33.71%) is better than 90.54% of its industry peers.
  • 1EXEL's Operating Margin has declined in the last couple of years.
  • The Gross Margin of 1EXEL (96.59%) is better than 94.59% of its industry peers.
  • 1EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
1EXEL.MI Yearly Profit, Operating, Gross Margins1EXEL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1EXEL is creating value.
  • 1EXEL has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 1EXEL has less shares outstanding
  • There is no outstanding debt for 1EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1EXEL.MI Yearly Shares Outstanding1EXEL.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
1EXEL.MI Yearly Total Debt VS Total Assets1EXEL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • 1EXEL has an Altman-Z score of 10.91. This indicates that 1EXEL is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of 1EXEL (10.91) is better than 86.49% of its industry peers.
  • 1EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 10.91
ROIC/WACC2.88
WACC8.75%
1EXEL.MI Yearly LT Debt VS Equity VS FCF1EXEL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

  • 1EXEL has a Current Ratio of 3.51. This indicates that 1EXEL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.51, 1EXEL is in the better half of the industry, outperforming 68.92% of the companies in the same industry.
  • A Quick Ratio of 3.44 indicates that 1EXEL has no problem at all paying its short term obligations.
  • 1EXEL's Quick ratio of 3.44 is fine compared to the rest of the industry. 1EXEL outperforms 68.92% of its industry peers.
Industry RankSector Rank
Current Ratio 3.51
Quick Ratio 3.44
1EXEL.MI Yearly Current Assets VS Current Liabilites1EXEL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 67.74% over the past year.
  • Measured over the past years, 1EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
  • The Revenue has grown by 10.73% in the past year. This is quite good.
  • The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.20% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, 1EXEL will show a quite strong growth in Revenue. The Revenue will grow by 10.31% on average per year.
EPS Next Y29.59%
EPS Next 2Y25.34%
EPS Next 3Y25.84%
EPS Next 5Y22.2%
Revenue Next Year7.2%
Revenue Next 2Y9.86%
Revenue Next 3Y11.44%
Revenue Next 5Y10.31%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1EXEL.MI Yearly Revenue VS Estimates1EXEL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
1EXEL.MI Yearly EPS VS Estimates1EXEL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.06, the valuation of 1EXEL can be described as rather expensive.
  • Based on the Price/Earnings ratio, 1EXEL is valued cheaply inside the industry as 85.14% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of 1EXEL to the average of the S&P500 Index (26.83), we can say 1EXEL is valued slightly cheaper.
  • The Price/Forward Earnings ratio is 12.20, which indicates a correct valuation of 1EXEL.
  • 1EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1EXEL is cheaper than 93.24% of the companies in the same industry.
  • 1EXEL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.95.
Industry RankSector Rank
PE 17.06
Fwd PE 12.2
1EXEL.MI Price Earnings VS Forward Price Earnings1EXEL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 1EXEL is valued cheaper than 85.14% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1EXEL indicates a rather cheap valuation: 1EXEL is cheaper than 91.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 12.66
EV/EBITDA 10.4
1EXEL.MI Per share data1EXEL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • 1EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
  • 1EXEL's earnings are expected to grow with 25.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.58
PEG (5Y)1.35
EPS Next 2Y25.34%
EPS Next 3Y25.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • 1EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

EXELIXIS INC

BIT:1EXEL (10/22/2025, 7:00:00 PM)

30.7

-2.85 (-8.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28
Earnings (Next)11-04
Inst Owners96.89%
Inst Owner ChangeN/A
Ins Owners2.23%
Ins Owner ChangeN/A
Market Cap8.26B
Revenue(TTM)2.23B
Net Income(TTM)602.30M
Analysts76.92
Price Target38.31 (24.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0.7%
EPS NQ rev (3m)3.36%
EPS NY rev (1m)1.43%
EPS NY rev (3m)4.85%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 17.06
Fwd PE 12.2
P/S 4.28
P/FCF 12.66
P/OCF 12.37
P/B 4.7
P/tB 4.85
EV/EBITDA 10.4
EPS(TTM)1.8
EY5.86%
EPS(NY)2.52
Fwd EY8.19%
FCF(TTM)2.42
FCFY7.9%
OCF(TTM)2.48
OCFY8.09%
SpS7.17
BVpS6.54
TBVpS6.33
PEG (NY)0.58
PEG (5Y)1.35
Graham Number16.27
Profitability
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROCE 32.1%
ROIC 25.22%
ROICexc 38.09%
ROICexgc 39.72%
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
FCFM 33.81%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 60.32%
Cap/Sales 0.81%
Interest Coverage 250
Cash Conversion 98.79%
Profit Quality 125.2%
Current Ratio 3.51
Quick Ratio 3.44
Altman-Z 10.91
F-Score8
WACC8.75%
ROIC/WACC2.88
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y29.59%
EPS Next 2Y25.34%
EPS Next 3Y25.84%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.2%
Revenue Next 2Y9.86%
Revenue Next 3Y11.44%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5YN/A
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%

EXELIXIS INC / 1EXEL.MI FAQ

Can you provide the ChartMill fundamental rating for EXELIXIS INC?

ChartMill assigns a fundamental rating of 8 / 10 to 1EXEL.MI.


Can you provide the valuation status for EXELIXIS INC?

ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (1EXEL.MI). This can be considered as Undervalued.


What is the profitability of 1EXEL stock?

EXELIXIS INC (1EXEL.MI) has a profitability rating of 8 / 10.


What are the PE and PB ratios of EXELIXIS INC (1EXEL.MI) stock?

The Price/Earnings (PE) ratio for EXELIXIS INC (1EXEL.MI) is 17.06 and the Price/Book (PB) ratio is 4.7.